Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/fmb-2020-0120 http://scihub22266oqcxt.onion/10.2217/fmb-2020-0120 33404263!7789744!33404263     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Future+Microbiol 2020 ; 15 (ä): 1747-1758 Nephropedia Template TP {{tp|p=33404263|t=2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients |pdf=|usr=}}{{33404263}} gab.com Text Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients JO: Future Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33404263 #FOAvip COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients. Twit Text FOAVip Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients ????Future Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33404263 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33404263 #FOAvip English Wikipedia <ref>{{Cite pmid|33404263}}</ref> Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients #MMPMID33404263 Ghanbari R; Teimoori A; Sadeghi A; Mohamadkhani A; Rezasoltani S; Asadi E; Jouyban A; Sumner SC Future Microbiol 2020[Dec]; 15 (ä): 1747-1758 PMID33404263show ga COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*therapeutic use[MESH] |Chymases/drug effects[MESH] |Coronavirus Papain-Like Proteases/drug effects[MESH] |Coronavirus RNA-Dependent RNA Polymerase/drug effects[MESH] |Drug Repositioning[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects[MESH] |Virus Internalization/drug effects[MESH]Existing antiviral options against SARS-CoV-2 replication in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing